KCNH2 and channelopathy: The approach has also been extended to hiPSC-CM models of LQTS type 2 (KCNH2 mutations), short QT syndrome type 1 [31], and calmodulin-associated LQTS [111], demonstrating its versatility across multiple genotypes and channelopathies.